Article summary
NEW YORK, July 30, 2026--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes…
Continue to the original publication for the complete article.